FULCRUM THERAPEUTICS

Fulcrum Therapeutics Announces Recent Business Highlights and Third Quarter 2022 Financial Results

08 Nov 2022 07:17:58 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Appoints Chief Medical Officer and Chief Scientific Officer

07 Nov 2022 17:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Tuesday, November 8, 2022 at 8:00 a.m. ET

02 Nov 2022 07:05:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® to Participate at Upcoming November Investor Conferences

01 Nov 2022 17:29:02 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Present New Data from the Open Label Extension of Phase 2 ReDUX4 Study at the World Muscle Society (WMS) Congress in Halifax, Canada

12 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Oct 2022 17:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09 Sep 2022 17:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate at Upcoming September Investor Conferences

06 Sep 2022 16:01:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® to Participate at the Upcoming Stifel 2022 Biotech Summer Summit

16 Aug 2022 07:05:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock

15 Aug 2022 21:28:02 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock

15 Aug 2022 16:08:15 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

11 Aug 2022 07:00:02 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Thursday, August 11, 2022 at 8:00 a.m. ET

04 Aug 2022 08:07:44 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Aug 2022 08:00:02 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

15 Jul 2022 08:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Departure of Chief Medical Officer

11 Jul 2022 17:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial of Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)

05 Jul 2022 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Jun 2022 16:02:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Proof-of-Concept for FTX-6058 in Sickle Cell Disease Based on Initial Data from the Ongoing Phase 1b Trial

10 Jun 2022 07:02:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Present Initial Data from Phase 1b Trial of FTX-6058 in Adults Living with Sickle Cell Disease at the European Hematology Association (EHA) Hybrid Congress in Vienna, Austria

12 May 2022 17:08:53 By Nasdaq GlobeNewswire